VEGFR3 suppression through miR‐1236 inhibits proliferation and induces apoptosis in ovarian cancer via ERK1/2 and AKT signaling pathways
- 15 March 2023
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 124 (5), 674-686
- https://doi.org/10.1002/jcb.30395
Abstract
Vascular endothelial growth factor receptor 3 (VEGFR3) is expressed in cancer cell lines and exerts a critical role in cancer progression. However, the signaling pathways of VEGFR3 in ovarian cancer cell proliferation remain unclear. This study aimed to demonstrate the signaling pathways of VEGFR3 through the upregulated expression of miR-1236 in ovarian cancer cells. We found that the messenger RNA and protein of VEGFR3 were expressed in the ovarian cancer cell lines, but downregulated after microRNA-1236 (miR-1236) transfection. The inhibition of VEGFR3, using miR-1236, significantly reduced cell proliferation, clonogenic survival, migration, and invasion ability in SKOV3 and OVCAR3 cells (p < 0.01). The flow cytometry results indicated that the rate of apoptotic cells in SKOV3 (38.65%) and OVCAR3 (41.95%) cells increased following VEGFR3 inhibition. Moreover, VEGFR3 stimulation (using a specific ligand, VEGF-CS) significantly increased extracellular signal-regulated kinase 1/2 (ERK1/2) and protein kinase B (AKT) phosphorylation (p < 0.01), whereas VEGFR3 suppression reduced p-ERK1/2 (67.94% in SKOV3 and 93.52% in OVCAR3) and p-AKT (59.56% in SKOV3 and 78.73% in OVCAR3) compared to the VEGF-CS treated group. This finding demonstrated that miR-1236 may act as an endogenous regulator of ERK1/2 and AKT signaling by blocking the upstream regulator of VEGFR3. Overall, we demonstrated the important role of the miR-1236/VEGFR3 axis in ovarian cancer cell proliferation by regulating the ERK1/2 and AKT signaling that might be an effective strategy against ovarian cancer.Keywords
This publication has 37 references indexed in Scilit:
- Tumor angiogenesis and lymphangiogenesis: Tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanismsLife Sciences, 2013
- MicroRNA Control of Vascular Endothelial Growth Factor Signaling Output During Vascular DevelopmentArteriosclerosis, Thrombosis, and Vascular Biology, 2013
- The Role of the VEGF-C/VEGFRs Axis in Tumor Progression and TherapyInternational Journal of Molecular Sciences, 2012
- The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approachesEmerging Therapeutic Targets, 2012
- Mirtron MicroRNA-1236 Inhibits VEGFR-3 Signaling During Inflammatory LymphangiogenesisArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Recent progress in the diagnosis and treatment of ovarian cancerCA: A Cancer Journal for Clinicians, 2011
- Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo.Cell Cycle, 2009
- The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cellsCancer Cell, 2006
- VEGF-receptor signal transductionTrends in Biochemical Sciences, 2003
- Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3The EMBO Journal, 2001